Full Press Release Details
Pharmaceuticals to Present at the
UBS Global Health Care Conference
VICTORIA, British Columbia--(BUSINESS WIRE)--May 19, 2015--Aurinia
Pharmaceuticals Inc., (NASDAQ: AUPH / TSX: AUP) today announced that its
Chief Executive Officer, Stephen W. Zaruby, will present a corporate
overview of the company at the 2015 UBS Global Health Care Conference,
taking place May 18th - 20th, 2015 in New
York at the Sheraton New York Times Square Hotel.
Aurinia Presentation Details
Time: 11:30 a.m. Eastern
Sheraton Time Square Hotel - Riverside Room
Aurinia is a clinical stage pharmaceutical company focused on the global
nephrology market. It is currently enrolling patients in its Phase 2b
clinical trial to evaluate the efficacy of its drug, voclosporin, as a
treatment for lupus nephritis ("LN"). LN is an inflammation of the
kidneys, that if inadequately treated can lead to end-stage renal
disease, making LN a serious and potentially life-threatening condition.
Voclosporin is a novel and potentially best in class calcineurin
inhibitor ("CNI") with extensive clinical data in over 2,000 patients in
other indications. Voclosporin is made by a modification of a single
amino acid of the cyclosporine molecule (a CNI approved for use in
transplant patients since 1983). This modification results in a more
predictable pharmacokinetic and pharmacodynamic relationship, an
increase in potency vs. cyclosporine, an altered metabolic profile, and
potential for flat dosing.
Visit www.auriniapharma.com for more information.
Aurinia Pharmaceuticals Inc.